Last reviewed · How we verify
intravenous iclaprim or intravenous linezolid
intravenous iclaprim or intravenous linezolid is a Oxazolidinone antibiotic Small molecule drug developed by Arpida AG. It is currently in Phase 3 development for Complicated skin and skin structure infections, Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.
Iclaprim inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit.
Iclaprim inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Used for Complicated skin and skin structure infections, Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.
At a glance
| Generic name | intravenous iclaprim or intravenous linezolid |
|---|---|
| Sponsor | Arpida AG |
| Drug class | Oxazolidinone antibiotic |
| Target | 50S ribosomal subunit |
| Modality | Small molecule |
| Therapeutic area | Infectious disease |
| Phase | Phase 3 |
Mechanism of action
Iclaprim is a synthetic antibiotic that selectively inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. This action prevents the formation of the 70S initiation complex, thereby inhibiting protein synthesis and ultimately leading to bacterial cell death.
Approved indications
- Complicated skin and skin structure infections
- Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia
Common side effects
- Thrombocytopenia
- Neutropenia
- Anemia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- intravenous iclaprim or intravenous linezolid CI brief — competitive landscape report
- intravenous iclaprim or intravenous linezolid updates RSS · CI watch RSS
- Arpida AG portfolio CI
Frequently asked questions about intravenous iclaprim or intravenous linezolid
What is intravenous iclaprim or intravenous linezolid?
How does intravenous iclaprim or intravenous linezolid work?
What is intravenous iclaprim or intravenous linezolid used for?
Who makes intravenous iclaprim or intravenous linezolid?
What drug class is intravenous iclaprim or intravenous linezolid in?
What development phase is intravenous iclaprim or intravenous linezolid in?
What are the side effects of intravenous iclaprim or intravenous linezolid?
What does intravenous iclaprim or intravenous linezolid target?
Related
- Drug class: All Oxazolidinone antibiotic drugs
- Target: All drugs targeting 50S ribosomal subunit
- Manufacturer: Arpida AG — full pipeline
- Therapeutic area: All drugs in Infectious disease
- Indication: Drugs for Complicated skin and skin structure infections
- Indication: Drugs for Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia